Bank of Montreal Can Purchases New Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Bank of Montreal Can purchased a new position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 98,331 shares of the company’s stock, valued at approximately $402,000. Bank of Montreal Can owned approximately 0.14% of Zentalis Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Anfield Capital Management LLC acquired a new position in Zentalis Pharmaceuticals in the second quarter worth $40,000. SG Americas Securities LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $58,000. American Century Companies Inc. acquired a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at $95,000. 49 Wealth Management LLC bought a new position in shares of Zentalis Pharmaceuticals in the 1st quarter valued at approximately $172,000. Finally, Kennedy Capital Management LLC acquired a new position in Zentalis Pharmaceuticals in the 1st quarter valued at $189,000.

Zentalis Pharmaceuticals Trading Down 2.3 %

ZNTL opened at $2.94 on Friday. The stock has a market cap of $208.82 million, a PE ratio of -0.88 and a beta of 1.70. Zentalis Pharmaceuticals, Inc. has a 1-year low of $2.83 and a 1-year high of $21.34. The stock’s fifty day simple moving average is $3.37 and its 200 day simple moving average is $7.35.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same period last year, the company earned ($1.85) EPS. Equities analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on ZNTL. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a report on Monday, August 12th. UBS Group downgraded shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $28.00 to $5.00 in a research note on Thursday, June 20th. Wells Fargo & Company lowered shares of Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $29.00 to $9.00 in a report on Tuesday, June 18th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, August 12th. Finally, Stifel Nicolaus decreased their price target on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, June 18th. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $10.78.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.